Literature DB >> 25564585

Low serum free thyroxine level in a girl with McCune-Albright syndrome.

Mart Roosimaa1, Anett Pajuväli2, Aleksandr Peet3, Vallo Tillmann4.   

Abstract

A 17-year-old girl with McCune-Albright syndrome (MAS) was suspected of having central hypothyroidism based on an inappropriately normal thyroid-stimulating hormone (TSH) and low free thyroxine (fT4). She was clinically euthyroid and her pituitary appeared normal on MRI. Treatment of hypothyroidism with levothyroxine resulted in suppression of TSH with a low fT4 and high free triiodothyronine (fT3) concentration and hence iatrogenic hyperthyroidism was diagnosed. After discontinuation of levothyroxine, the TSH and fT3 normalised while fT4 remained low. Increased conversion of thyroxine (T4) to triiodothyronine (T3) can be part of MAS. Therefore, fT3 and fT4 should both be measured when evaluating thyroid function in patients with MAS. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25564585      PMCID： PMC4289761          DOI： 10.1136/bcr-2014-206497

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  11 in total

1.  The role of type 1 and type 2 5'-deiodinase in the pathophysiology of the 3,5,3'-triiodothyronine toxicosis of McCune-Albright syndrome.

Authors:  Francesco S Celi; Giuseppe Coppotelli; Aaron Chidakel; Marilyn Kelly; Beth A Brillante; Thomas Shawker; Natasha Cherman; Penelope P Feuillan; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2008-03-18       Impact factor: 5.958

2.  Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome.

Authors:  W F Schwindinger; C A Francomano; M A Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

Review 3.  Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism.

Authors:  Wilmar M Wiersinga
Journal:  Nat Rev Endocrinol       Date:  2014-01-14       Impact factor: 43.330

4.  Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.

Authors:  Rebecca S Bahn; Henry B Burch; David S Cooper; Jeffrey R Garber; M Carol Greenlee; Irwin Klein; Peter Laurberg; I Ross McDougall; Victor M Montori; Scott A Rivkees; Douglas S Ross; Julie Ann Sosa; Marius N Stan
Journal:  Endocr Pract       Date:  2011 May-Jun       Impact factor: 3.443

5.  Thyroid abnormalities in the McCune-Albright syndrome: ultrasonography and hormonal studies.

Authors:  P P Feuillan; T Shawker; S R Rose; J Jones; R K Jeevanram; B C Nisula
Journal:  J Clin Endocrinol Metab       Date:  1990-12       Impact factor: 5.958

6.  Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with 3,5,3'-triiodothyronine-predominant Graves' disease.

Authors:  Mitsuru Ito; Nagaoki Toyoda; Emiko Nomura; Yuuki Takamura; Nobuyuki Amino; Toshiji Iwasaka; Junta Takamatsu; Akira Miyauchi; Mitsushige Nishikawa
Journal:  Eur J Endocrinol       Date:  2010-10-11       Impact factor: 6.664

7.  Activating mutations of the stimulatory G protein in the McCune-Albright syndrome.

Authors:  L S Weinstein; A Shenker; P V Gejman; M J Merino; E Friedman; A M Spiegel
Journal:  N Engl J Med       Date:  1991-12-12       Impact factor: 91.245

8.  Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients.

Authors:  Damiano Gullo; Adele Latina; Francesco Frasca; Rosario Le Moli; Gabriella Pellegriti; Riccardo Vigneri
Journal:  PLoS One       Date:  2011-08-01       Impact factor: 3.240

Review 9.  McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia.

Authors:  Michael T Collins; Frederick R Singer; Erica Eugster
Journal:  Orphanet J Rare Dis       Date:  2012-05-24       Impact factor: 4.123

10.  McCune-Albright syndrome.

Authors:  Claudia E Dumitrescu; Michael T Collins
Journal:  Orphanet J Rare Dis       Date:  2008-05-19       Impact factor: 4.123
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.